This article is protected by copyright. All rights reserved.Peer reviewedPostprin
Context Novel therapies have improved the remission rate in chronic inflammatory disorders including...
Objective. To describe the use of and response to biologic therapies commenced in adults with JIA. M...
BACKGROUND: Data from routine clinical practice are needed to further define the efficacy and safety...
OBJECTIVE: to assess the time in remission after discontinuing biologic therapy in JIA patients. MET...
OBJECTIVE: To assess the time in remission after discontinuing biologic therapy in patients with ju...
BACKGROUND: Biologic disease-modifying antirheumatic drugs (bDMARDs) have changed the treatment of j...
Background: many Juvenile Idiopathic Arthritis (JIA) patients reach inactivity while medicated, but ...
Publisher Copyright: © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No co...
© 2018, American College of Rheumatology Objective: To determine the frequency, time to flare, and p...
The advent of biologic medications has increased considerably the potential for treatment benefit in...
PREDICTIVE FACTORS OF REMISSION IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS TREATED WITH BIOLOGICAL TH...
Background: Data from routine clinical practice are needed to further define the efficacy and safety...
BACKGROUND: Children with juvenile idiopathic arthritis (JIA) who achieve a drug free remission ofte...
Context Novel therapies have improved the remission rate in chronic inflammatory disorders including...
Background: Biologic therapy has changed the prognosis of patients with juvenile idiopathic arthrit...
Context Novel therapies have improved the remission rate in chronic inflammatory disorders including...
Objective. To describe the use of and response to biologic therapies commenced in adults with JIA. M...
BACKGROUND: Data from routine clinical practice are needed to further define the efficacy and safety...
OBJECTIVE: to assess the time in remission after discontinuing biologic therapy in JIA patients. MET...
OBJECTIVE: To assess the time in remission after discontinuing biologic therapy in patients with ju...
BACKGROUND: Biologic disease-modifying antirheumatic drugs (bDMARDs) have changed the treatment of j...
Background: many Juvenile Idiopathic Arthritis (JIA) patients reach inactivity while medicated, but ...
Publisher Copyright: © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No co...
© 2018, American College of Rheumatology Objective: To determine the frequency, time to flare, and p...
The advent of biologic medications has increased considerably the potential for treatment benefit in...
PREDICTIVE FACTORS OF REMISSION IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS TREATED WITH BIOLOGICAL TH...
Background: Data from routine clinical practice are needed to further define the efficacy and safety...
BACKGROUND: Children with juvenile idiopathic arthritis (JIA) who achieve a drug free remission ofte...
Context Novel therapies have improved the remission rate in chronic inflammatory disorders including...
Background: Biologic therapy has changed the prognosis of patients with juvenile idiopathic arthrit...
Context Novel therapies have improved the remission rate in chronic inflammatory disorders including...
Objective. To describe the use of and response to biologic therapies commenced in adults with JIA. M...
BACKGROUND: Data from routine clinical practice are needed to further define the efficacy and safety...
DOI
Add to ORKG